Article
In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Leukemia - 1 May 2022
Gbyli Rana, Song Yuanbin, Liu Wei, Gao Yimeng, Biancon Giulia, Chandhok Namrata S, Wang Xiaman, Fu Xiaoying, Patel Amisha, Sundaram Ranjini, Tebaldi Toma, Mamillapalli Padmavathi, Zeidan Amer M, Flavell Richard A, Prebet Thomas, Bindra Ranjit S, Halene Stephanie
Abstract excerpt
Treatment options for patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are scarce. Recurring mutations, such as mutations in isocitrate dehydrogenase-1 and -2 (IDH1/2) are found in subsets of AML and MDS, are therapeutically targeted by mutant enzyme-specific small molecule inhibitors (IDHmi). IDH mutations induce diverse metabolic and epigenetic changes that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.